|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Here we demonstrate that treatment of breast cancer cells sensitive to EGFR TKIs with recombinant HGF confers a resistance to EGFR TKIs.
|
22788954 |
2012 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
In vitro and in vivo effects of suppressor of cytokine signalling 7 knockdown in breast cancer: the influence on cellular response to hepatocyte growth factor.
|
25162020 |
2014 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
The current study explored the impact of paxillin suppression on prostate and breast cancer cell function and their responsiveness to hepatocyte growth factor (HGF) and bone matrix extract (BME) in order to assess its potential to influence bone colonization and homing.
|
28739717 |
2017 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We examined HGF, the HGF receptor (c-Met), HGFA, matriptase, and the activation inhibitors (HAI-1 and HAI-2), tissues from patients with breast cancer.
|
14734471 |
2004 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
The biological function of the interaction between LINE-1 ORF-1p and the HGF/ETS-1 signaling pathway in regulation of human breast cancer proliferation remains largely unknown.
|
24012497 |
2013 |
|
Malignant neoplasm of breast
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The coding exons and flanking regions of HGF and MET were directly sequenced in 145 lymphedema probands, 59 unrelated women with secondary lymphedema following treatment for breast cancer, 21 individual patients with lymphedema and intestinal lymphangiectasia, and at least 159 unrelated ethnic matched control individuals.
|
18564920 |
2008 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Certain well-known oncogenes (MYC and HGF), cytokines (CSF2, IFNG and IL5) and microRNAs (miR-21, miR-155-5p and let-7) may participate in the ILF2 expression network in breast cancer.
|
30018709 |
2018 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Detection of hepatocyte growth factor/scatter factor receptor (c-Met) in axillary drainage after operations for breast cancer using reverse transcriptase-polymerase chain reaction.
|
12793903 |
2003 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Here, we investigated whether HGFK1 is a key regulator of breast cancer bone metastasis.
|
22767217 |
2012 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Retroviral ribozyme transgenes targeting HGF/SF in fibroblasts or its receptor cMET in mammary cancer cells can reduce the growth of mammary cancer and associated angiogenesis by inhibiting paracrine stromal-tumor cell interactions.
|
14519655 |
2003 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Extracellular superoxide dismutase inhibits hepatocyte growth factor-mediated breast cancer-fibroblast interactions.
|
29296173 |
2017 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Overexpression of LRIG1 destabilizes endogenous Met receptor in breast cancer cells and impairs their ability to respond to HGF.
|
17178829 |
2007 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
HGF/SF and c-met were determined in 73 breast cancers (median follow up: 61 months) and 10 samples of tumour-free breast tissue.
|
8837300 |
1996 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Deregulation of hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) signalling has been associated with poor clinical outcome in breast cancer and other cancers.
|
24910416 |
2014 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Hepatocyte growth factor enhances CXCR4 expression favoring breast cancer cell invasiveness.
|
16112111 |
2005 |